Abstract:Background Our previous study showed approximately 11% of Chinese RA patients combined with chronic Hepatitis B virus (HBV) infection and 32% with resolved HBV infection. HBV reactivation may occur as an adverse event of biologic DMARDs and TNFIs or abatacept have been categoried as moderate risk of HBV reactivation, rituximab as high risk [1]. However, tocilizumab (TCZ) is still unclassified due to few data. TCZ has been approved for RA patients in combination with csDMARDs by CFDA in November 2013 and most of Chinese RA patients can only afford short course of TCZ for self-paid and expensive price. Objectives To investigate the impact of short course of TCZ on HBV reactivation in RA patients. Methods RA patients with moderate or high disease activity were recruited. Three consecutive doses of intravenous TCZ were given combined with csDMARDs. RA disease activity, liver function and HBV infection status were evaluated at baseline, week 4, week 8 and week 12 during TCZ based therapy. Results Fifty-seven RA patients were recruited and 51 were qualified for statistics (Figure 1). They were divided into chronic HBV infection group (n=7, 13.7%), resolved HBV infection group (n=33, 64.7%) and non-HBV infection group (n=11, 21.6%). Three patients (6%) developed HBV reactivation after 1–3 doses of TCZ and all of them had chronic HBV infection without antiviral prophylaxis. All reactivation patients were asymptomatic along with normal aminotransferases and resolution of virological response after therapeutic antiviral therapy. None of patients with resolved HBV infection suffered from HBV reactivation. Aminotransferases elevated in 24% (12/51) of RA patients with 4% (2/51) exceeding 2-fold of ULN and returned to normal 4 weeks after adding hepatinica. Anti-HBs titer was positive (≥10 IU/L) in 82% (27/33) of patients with resolved HBV infection and reduced significantly after first dose of TCZ compared to baseline [426 (59–978) IU/L vs. 446 (78–000) IU/L, P<0.05], which was below protective level (<10 IU/L) in 19% (5/27) of patients and unable to recover in 7% (2/27) up to week 28–36. All patients were kept follow-up after 12 weeks. No additional HBV reactivation occurred during 4–80 weeks on extended period. Conclusions This real-world, prospective cohort study suggests that short course of TCZ has moderate risk of HBV reactivation in RA patients and high risk in RA patients with chronic HBV infection especially without antiviral prophylaxis, which indicate the importance of HBV screening and antiviral prophylaxis for patients with chronic HBV infection before starting TCZ therapy. References Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology, 2015,148:215–219. Acknowledgement This work was supported by National Natural Science Foundation of China (No. 81471597), Specialized Research Fund for the Doctoral Program of Higher Education (No.20130171110075) and Guangdong Natural Science Foundation (No.2014A030313074). Disclosure of Interest None declared

Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy

Anti-TNF therapy in patients with HBV infection—analysis of 87 patients with inflammatory arthritis

Hepatitis B reactivation risk and physician awareness in rheumatological patients receiving anti-tumor necrosis factor-α treatment

Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists

Role of Hepatitis B Surface Antibodies in Risk for Hepatitis B Virus Reactivation During Anti-Tumor Necrosis Factor Therapy

Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs

Size Matters! Anti-HBs Titer and HBV Reactivation During Anti-TNF Therapy

Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis

Hepatitis B Reactivation in Patients Receiving Direct-Acting Antiviral Therapy or Interferon-Based Therapy for Hepatitis C: A Systematic Review and Meta-Analysis

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

Hepatitis B virus Reactivation in Patients Receiving Tocilizumab for Rheumatoid Arthritis: A Long‐term, Retrospective Observational Study

Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies

Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors

Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study)

FRI0225 Short Course of Tocilizumab Increases Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Rheumatoid Arthritis: A Real-World, Prospective Cohort Study

Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases

Risk of HBV Reactivation in Patients with Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management

Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan

Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients

Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy